Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40results about How to "Reduce Lipid Deposition" patented technology

Applications of benzenesulfonamido benzamide compound in treatment of non-alcoholic fatty liver diseases

PendingCN108938615APromote phosphorylationPrevent and/or treat inflammatory responsesAntipyreticMetabolism disorderLiver and kidneyLiver tissue
The invention belongs to the technical field of medicine, and relates to applications of a benzenesulfonamido benzamide compound in preparation of medicines used for treatment of non-alcoholic fatty liver diseases. It is confirmed through study on influences on golden hamster weight and liver and kidney index, influences on the contents of ALT and AST in golden hamster serum, influences on goldenhamster serum and blood fat relates indexes, influences on the content of fat in golden hamster livers, and influences on golden hamster liver tissue pathogeny structures that the benzenesulfonamido benzamide compound possesses excellent activity in treatment of non-alcoholic fatty liver diseases, and it is promising for the benzenesulfonamido benzamide compound to be developed into medicines usedfor treatment of non-alcoholic fatty liver diseases.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI

Application of novel loquat leaf sesquiterpene glycoside in relieving liver cell lipid deposition

The invention discloses application of novel loquat leaf sesquiterpene glycoside in relieving liver cell lipid deposition, and also discloses application in preparation of drugs and health-care foodsfor preventing or treating non-alcoholic fatty liver. The name of the sesquiterpene glycoside is nerolidol-3-O-alpha-L-arabinopyranosyl-(1->4)-alpha-L-rhamnopyranosyl-(1-> 2)-[alpha-L-rhamnopyranosyl-(1-> 6)]-beta-D-glucopyranoside.
Owner:INST OF BOTANY JIANGSU PROVINCE & CHINESE ACADEMY OF SCI

Medicinal preparation of oral dropps with blood-activating Chinese medicine notogiseng and leech extract preparation

A dripping pill for treating DIC, coronary heart disease, angina pectoris, acute myocardiac infarction, ischemic cerebral apoplexy, hyperlipemia, etc is preportionally prepared from notoginseng and leech through extracting.
Owner:王维和

Traditional Chinese medicinal formula for treating hypertension

InactiveCN105687603AReduce Lipid DepositionReduces lipid deposits in the aortic wallCardiovascular disorderPlant ingredientsMedicinal herbsSide effect
The invention relates to a traditional Chinese medicinal formula, and especially relates to a traditional Chinese medicinal formula for treating hypertension. The formula comprises 15-36g of prepared rehmannia root, 6-20g of Cornus officinalis, 6-20g of Chinese yam, 3-15g of Poria cocos, 3-20g of Rhizoma Alismatis, 3-20g of Cortex Moutan, 2-15g of tangerine pericarp, 2-15g of cassia seed, 2-10g of cinnamon and 5-15g of Achyranthes bidentata. The formula aims at the main reasons of hyperactivity of liver-yang, yang hyperactivity and yin deficiency of hypertension patients, and nourishes liver and kidney yin to reduce lipid deposition on aorta walls, reduce blood fat and improve kidney functions in order to reduce the blood pressure. The above formula also has blood sugar reducing, liver cell protecting and tumor preventing effects, realizes simultaneous treatment of principal and subordinate symptoms, and has no toxic or side effects. When the formula is clinically taken by 236 patients, the effective rate is 100%, and the cure rate is 93.6% or above.
Owner:李锐

Traditional Chinese medicine preparation for treating fatty liver

The invention discloses a traditional Chinese medicine preparation for treating the fatty liver. The traditional Chinese medicine preparation is prepared from effective ingredients and medically acceptable auxiliary materials. The effective ingredients comprise, by weight, 5%-30% of codonopsis pilosula, 5%-30% of rhizoma alismatis, 5%-30% of the root of kudzu vine, 4%-10% of panax notoginseng, 5%-25% of the root of red-rooted salvia, 5%-15% of pollen typhae, 5%-30% of prepared fleece flower roots, 5%-30% of serrate rabdosia herb and 5%-30% of serrate rabdosia herbs. Codonopsis pilosula in the traditional Chinese medicine preparation can invigorate the spleen to eliminate dampness and serves as a monarch drug. Rhizoma alismatis, the root of kudzu vine and serrate rabdosia herb can resolve dampness and relieve internal heat of fever, and panax notoginseng, the root of red-rooted salvia and pollen typhae can promote blood circulation to remove blood stasis and serve as a ministerial drug. Prepared fleece flower roots can tonify the kidney and nourish the lever, lychee seeds can promote the circulation of qi and remove stasis and serves as an adjuvant drug, the nine kinds of medicine are used together, the functions of invigorating the spleen to eliminate dampness and invigorating the circulation of blood and tonifying the kidney are achieved together, then liver lipidosis is restrained, liver fat is promoted to be degraded, liver lipidosis is reduced, and the remarkable curative effect on the fatty liver is achieved.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE

Novel application of rhizoma cimicifugae and extract thereof

The invention discloses a novel application of rhizoma cimicifugae and an extract thereof. According to the invention, it is discovered that the rhizoma cimicifugae, an alcohol extract of the rhizomacimicifugae and an ethyl acetate phase extract of the rhizoma cimicifugae are obvious in weight losing and blood glucose reducing effects, and weight losing and blood glucose reducing effects of a natural compound, namely actinodaphnine, in the ethyl acetate phase extract of the rhizoma cimicifugae are confirmed. The actinodaphnine is a 9,19-cycloartane triterpenoid saponin compound. Based upon animal experiments, it is proved that the actinodaphnine can prevent the formation of obesity induced by high fat diets, and moreover, the actinodaphnine can treat the formed obesity induced by high fatdiets and can improve obesity-related sugar intolerance, insulin resistance and hepatic injury. The rhizoma cimicifugae, the alcohol extract of the rhizoma cimicifugae, the ethyl acetate phase extract of the rhizoma cimicifugae and the actinodaphnine can be used for preparing medicines or health-care products for losing weight, reducing blood glucose and protecting liver.
Owner:HEFEI UNIV OF TECH +1

Application of medicines for promoting non-alcoholic fatty liver cell lipid metabolism

The invention discloses an application of medicines for promoting non-alcoholic fatty liver cell lipid metabolism, and particularly relates to an application of an activated monomer component namely asiatic acid of a traditional Chinese medicine namely herba potentillae chinensis. The monomer compound namely the asiatic acid can be separated from the traditional Chinese medicine namely herba potentillae chinensis, so that the asiatic acid can be proved to effectively restrain activation and multiplication of non-alcoholic fatty liver cells, and lipidoses, oxidation stress and an inflammatory reaction in the non-alcoholic fatty liver cells can be alleviated. The non-alcoholic fatty liver cell lipid metabolism can be improved. The traditional Chinese medicine monomer can relieve the problemthat the non-alcoholic fatty liver is poor in treatment effects, and a novel compound being clear in chemical structure and efficient can be provided for treatment of non-alcoholic fatty liver.
Owner:GUANGXI MEDICAL UNIVERSITY

Application of polysaccharide of flowers of Apios americana Medikus to reduction of lipidosis in hepatocytes

The invention discloses application of the polysaccharide of the flowers of Apios americana Medikus to reduction of lipidosis in hepatocytes. A preparation method for the polysaccharide of the flowersof Apios americana Medikus comprises the following steps: 1) preparation of a crude polysaccharide product of the flowers of Apios americana Medikus: mixing the flowers of Apios americana Medikus with distilled water, carrying out extraction at first, then carrying out smashing, centrifugation and concentration, adding ethanol in the obtained concentrate until the final concentration of ethanol is 80 + / - 5%, carrying out standing at 4 + / - 1 DEG C for 24 + / - 2 h, and then collecting a precipitate so as to obtain the crude polysaccharide product of the flowers of Apios americana Medikus; and 2)purification of the crude polysaccharide product of the flowers of Apios americana Medikus: subjecting the crude polysaccharide product of the flowers of Apios americana Medikus to decoloring with active carbon and Sevage-process deproteinization.
Owner:ZHEJIANG UNIV

Application of taro tuber ethanol extract in reducing liver cell lipidosis

ActiveCN107823247AReduces lipid deposition in LO2 cellsGood development prospectsMetabolism disorderDigestive systemChemistryFormic acid
The invention discloses application of a taro tuber ethanol extract in reducing liver cell lipidosis. The application refers to preparation of medicines and healthcare foods for treating or preventingnon-alcoholic fatty liver diseases. A preparation method of the taro tuber ethanol extract comprises the following steps: mixing taro tubers with 95% ethanol with 0.1mol / L of hydrochloric acid, pulping, performing ultrasonic extraction, and centrifuging to obtain supernate; concentrating the supernate, and performing separation purification on the obtained concentrated liquid with macroporous resin; using a 1% formic acid solution as an eluting agent and a methanol solution with 0.2% of formic acid as an eluent, and collecting an elution liquid; concentrating the elution liquid, pre-freezingthe pulp concentrated liquid at minus 70 DEG C to minus 90 DEG C firstly, and further drying by a vacuum freeze-drying machine, thereby obtaining powder, namely the taro tuber ethanol extract.
Owner:ZHEJIANG UNIV

Application of KLF4-based salidroside to resisting vascular endothelial cell senescence

The invention relates to an application of KLF4-based salidroside to resisting vascular endothelial cell senescence, in particular to an application of salidroside to respects of endothelial cells damage caused by Hcy, restraining of active oxygen level rise induced by Hcy, preparations for resisting vascular endothelial cell senescence and the like. The result indicates that the salidroside exerts important effects in the endothelial cells senescence induced by Hcy, and the mechanism of the salidroside is mainly based on adjustment and control of a transcription factor KLF4.
Owner:GUIZHOU MEDICAL UNIV

Drug combination composition for type 2 diabetes and liver injury and application of drug combination composition

The invention provides a drug combination composition for type 2 diabetes and liver injury and an application of the drug combination composition, and belongs to the field of biological medicine. The drug combination composition comprises selenium-enriched probiotics and thiazolidinedione medicine pioglitazone, and experiments of a type 2 diabetes mouse model constructed by combining high-fat feeding with STZ injection find that after the selenium-enriched probiotics DD98 and the pioglitazone are combined for administration, the weight and fasting blood glucose of the mouse can be obviously improved, liver lipid deposition, oxidative stress and inflammation levels can be reduced, and liver tissue damage can be relieved, so that the administration dosage of the pioglitazone is reduced, and a basis is provided for clinically avoiding side effects of the pioglitazone.
Owner:JIANGSU DAYSEBIOTECH LTD +1

Application and preparation method of exocarpium citrus grandis tea

The present invention belongs to the technical field of tea applications, specifically relates to an application of exocarpium citrus grandis tea, and more specifically relates to the application of the exocarpium citrus grandis tea in preparing medicines or food for relieving non-alcoholic fatty liver. The exocarpium citrus grandis tea is applied in preparation of products for relieving the non-alcoholic fatty liver, especially the application of the exocarpium citrus grandis tea in the preparing the medicines / food for relieving the non-alcoholic fatty liver, which is the key protection scopeof the present invention. The exocarpium citrus grandis tea is any one of exocarpium citrus grandis black tea, exocarpium citrus grandis yellow tea and exocarpium citrus grandis green tea. The provided exocarpium citrus grandis tea can significantly reduce lipid deposition in a HepG 2 cell model, can up-regulate p-AMPK / AMPK, p-ACC / ACC and CPT-1 to promote lipid oxidation by regulating an AMPK signaling pathway, down-regulates expressions of SREBP1c and FAS proteins to inhibit fat synthesis, so as to reduce fat deposition in liver cells, so that the non-alcoholic fatty liver disease caused byhigh-fat diet, bad habits, etc. can be improved and the exocarpium citrus grandis tea has an obvious function for relieving the non-alcoholic fatty liver.
Owner:TEA RES INST GUANGDONG ACAD OF AGRI SCI

Application of formononetin to treatment of nonalcoholic fatty liver disease

The invention discloses an application of formononetin to treatment of nonalcoholic fatty liver disease. An in vitro and an in vitro cell model are adopted, formononetin is used for treating animals,and the improvement effect of the formononetin on metabolic syndromes of nonalcoholic fatty liver, obesity, insulin resistance, lipid disorders and the like can be observed. Experiment proves that theformononetin can notably reduce weight, liver weight / body mass indexes, liver triglyceride(TG), liver lipidoses, liver function damage criterion-millet straw aminopherase (AST) and alanine aminotransferase (ALT) of organisms suffering from nonalcoholic fatty liver, and besides, can improve insulin resistance. Blood biochemistry detection indicates that the formononetin can also reduce the level of triglyceride (TG), cholesterol (TC) and low intensity lipoprotein (LDL-C) of HFD mice, and can improve the lipid disorders. The formononetin has important effects on treatment of nonalcoholic fattyliver.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Application of taro leaf alcohol extract in reducing hepatic cell lipidosis

The invention discloses application of taro leaf alcohol extract in reducing hepatic cell lipidosis and preparation for drug and healthcare food for treating or preventing the non-alcoholic fatty liver disease. A preparation method for the taro leaf alcohol extract comprises the following steps: mixing and pulping taro leaves and 85% alcohol containing 0.1 mol / L of hydrochloric acid, ultrasonically extracting and centrifuging to obtain liquid supernatant; rotatably evaporating and concentrating the liquid supernatant in a rotary evaporator; and separating and purifying concentrated solution through macroporous resin, taking an methanol aqueous solution containing 0.05% of formic acid as an eluent; rotatably evaporating and concentrating eluant, pre-freezing the slurry concentrated solution, drying the slurry into powder through a vacuum-freezing dryer, thereby obtaining taro leaf alcohol extract.
Owner:ZHEJIANG UNIV

Long-chain non-coding RNA AAGNCR and application thereof

The invention belongs to the technical field of molecular biology, and particularly relates to a long-chain non-coding RNA AAGNCR and application thereof in prediction of intramuscular fat content ofpigs. The objective existence of AAGNCR is proved through RT-PCR, and meanwhile it is proved that AAGNCR has a promoting effect on intramuscular adipose cell lipid deposition. The AAGNCR siRNA sequence for inhibiting the expression of the AAGNCR sequence is synthesized by aiming at the AAGNCR sequence, and the sequence can obviously reduce the expression quantity of the AAGNCR in cells and has anobvious inhibition effect on the expression of the AAGNCR.
Owner:INST OF ANIMAL HUSBANDRY & VETERINARY MEDICINE HENAN ACAD OF AGRI SCI

Application of FDPS (farnesyl pyrophosphate synthase) for preparing medicine capable of treating nonalcoholic steatohepatitis

The invention utilizes a high-fat high-sugar diet induced nonalcoholic steatohepatitis (short for NASH) mouse, discloses that farnesyl pyrophosphate synthase (FDPS) can be used as a potential therapeutic target for the NASH, proves a treatment function of the antagonist, i.e., alendronate sodium, of the FDPS for the NASH, and provides a new thought for developing NASH treatment medicines.
Owner:CHINA PHARM UNIV

Application of total glycosides of Cistanche deserticola and echinacoside in the preparation of drugs for preventing and treating alcoholic liver injury with intestinal injury

The invention provides the application of total glycosides of cistanche deserticola and echinacoside in the preparation of medicines for preventing and treating alcoholic liver injury accompanied by intestinal injury and regulating intestinal flora. The results of pharmacological experiments showed that in the mouse model of alcoholic liver injury, total glycosides of cistanche and echinacoside could reduce the damage of liver tissue morphology in mice, reduce the lipid deposition in the liver of mice, and reduce the alanine aminotransferase (ALT) in mouse liver. ) and aspartate aminotransferase (AST) content, reduce the oxidative damage of mouse liver, reduce the damage of harmful substances such as endotoxin to the liver, and at the same time, it can also reduce the damage of mouse small intestine tissue morphology, improve the integrity of intestinal wall villi, and regulate intestinal The flora is disturbed. It can be seen that the present invention has the prospect of being developed into a drug capable of simultaneously protecting alcoholic liver injury and alcoholic intestinal injury, and has important clinical significance and commercial value.
Owner:PEKING UNIV

Application of chrna4 in the preparation of drugs for the treatment of nonalcoholic steatohepatitis

The present invention utilizes high-fat and high-sugar diet-induced nonalcoholic steatohepatitis (NASH) mice to reveal that CHRNA4 can be used as a potential therapeutic target for NASH, and confirms the effect of its antagonist lobeline hydrochloride on NASH. Therapeutic effect provides a new way for the treatment of NASH.
Owner:CHINA PHARM UNIV

Application of Apios americana Medikus leaf polysaccharide to reduction of hepatocyte lipid deposition

The invention discloses application of Apios americana Medikus leaf polysaccharide to reduction of hepatocyte lipid deposition. The Apios americana Medikus leaf polysaccharide is used for preparing medicines and health-care foods, which are used for treating or preventing nonalcoholic fatty liver. A preparation method of the Apios americana Medikus leaf polysaccharide comprises the following steps: 1) preparing an Apios americana Medikus leaf polysaccharide crude product: after mixing Apios americana Medikus leaves and distilled water, extracting; then pulping, centrifuging and concentrating;adding ethanol into an obtained concentrated solution until the final concentration of the ethanol is 85+ / -5 percent; standing at 4+ / -1 DEG C for 24+ / -2h; then collecting sediment to obtain Apios americana Medikus leaf crude polysaccharide; 2) purifying the Apios americana Medikus leaf crude polysaccharide, including carrying out activated carbon decoloration and Sevage-method protein removal on the Apios americana Medikus leaf crude polysaccharide.
Owner:ZHEJIANG UNIV

Application of atractylenolide III in preparation of medicine for treating non-alcoholic fatty liver disease

The invention relates to an application of atractylenolide III in preparation of a medicine for treating a non-alcoholic fatty liver disease. It is found that atractylenolide III can reduce liver lipid deposition, reduce liver indexes, significantly reduce serum blood fat levels and liver tissue TG and TC levels and activate related signal molecules of an AMPK / SIRT1 signal channel; the MDA level can be reduced, the SOD and GSH-Px levels are increased, and the oxidative stress is improved. The atractylenolide III can inhibit lipid deposition by activating an AMPK / SIRT1 signal channel, reduce the oxidative stress reaction of liver cells, improve the expression level of CPT1A and improve the oxidative stress of mitochondria at the same time, and play a role in treating the non-alcoholic fatty liver disease through the mechanism. The atractylenolide III is a plant-derived chemical substance, the preparation steps are simple, the environmental pollution is small, and the method is suitable for industrial production. Therefore, atractylenolide III can be used for preparing the medicine or health food for treating the non-alcoholic fatty liver disease.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M

Application of taro flower polysaccharide in reducing lipid deposition in liver cells

The invention discloses application of the polysaccharide of the flowers of Apios americana Medikus to reduction of lipidosis in hepatocytes. A preparation method for the polysaccharide of the flowersof Apios americana Medikus comprises the following steps: 1) preparation of a crude polysaccharide product of the flowers of Apios americana Medikus: mixing the flowers of Apios americana Medikus with distilled water, carrying out extraction at first, then carrying out smashing, centrifugation and concentration, adding ethanol in the obtained concentrate until the final concentration of ethanol is 80 + / - 5%, carrying out standing at 4 + / - 1 DEG C for 24 + / - 2 h, and then collecting a precipitate so as to obtain the crude polysaccharide product of the flowers of Apios americana Medikus; and 2)purification of the crude polysaccharide product of the flowers of Apios americana Medikus: subjecting the crude polysaccharide product of the flowers of Apios americana Medikus to decoloring with active carbon and Sevage-process deproteinization.
Owner:ZHEJIANG UNIV

Oral spray for losing weight

The invention belongs to the technical field of oral spray, and particularly relates to an oral spray for losing weight, which comprises the following raw materials: 8-16 parts of chieh-qua, 8-16 parts of garcinia cambogia peel, 8-16 parts of gymnema sylvestre leaves, 5-15 parts of yellow cherry pepper, 5-10 parts of guarana, 4-10 parts of apios americana medikus leaves, 4-10 parts of paper mulberry leaves, 4-7 parts of red raspberry, 4-7 parts of fructus piperis longi, 3-8 parts of cleistocalyx operculatus, 3-8 parts of grifola frondosa, 3-8 parts of cornflower and 1-3 parts of menthol. After chieh-qua, garcinia cambogia peel, gymnema sylvestre leaves, yellow cherry peppers, guarana, apios americana medikus leaves, paper mulberry leaves, red raspberry, fructus piperis longi, cleistocalyx operculatus, grifola frondosa, cornflowers and menthol are combined together to form the oral spray, carbohydrates in various foods can be inhibited from being converted into fat in vivo, fat metabolism can be improved, carbohydrate metabolic balance can be adjusted, absorption of saccharides in small intestines can be inhibited, blood sugar can be stabilized, hunger sensation can be delayed, basic energy daily required by the body can be supplied and supplemented, the physical ability level can be enhanced and the health-care weight-losing effect can be comprehensively realized from multiple angles.
Owner:深圳市巨印科技有限公司

Application of AKT2 inhibitor in preparation of medicine for treating non-alcoholic fatty liver disease

The invention discloses an application of an AKT2 inhibitor in the preparation of a medicine for treating a non-alcoholic fatty liver disease, and belongs to the technical field of biological medicines. Pharmacological experiment results prove that the AKT2 inhibitor (CCT128930) has a good treatment effect on an L02 cell lipid deposition model induced by free fatty acid for the first time, lipid deposition in cells and ROS level in cytoplasm are reduced, and Caspase 3 enzyme activity can be reduced, so that cell apoptosis caused by free fatty acid is reduced. The AKT2 inhibitor is used for preparing the medicine for treating the non-alcoholic fatty liver disease, the curative effect is definite, the effect is obvious, the side effect is low, and the medical application prospect is wide.
Owner:CHINA PHARM UNIV

The application of taro leaf polysaccharide in reducing lipid deposition in liver cells

The invention discloses an application of bean taro leaf polysaccharide in reducing lipid deposition in liver cells; it is used for preparing medicine and health food for treating or preventing non-alcoholic fatty liver. The preparation method of the bean taro leaf polysaccharide is as follows: 1), the preparation of the crude product of the bean taro leaf polysaccharide: first extract the bean taro leaf and distilled water, then beat, centrifuge, and concentrate; add ethanol to the obtained concentrated solution The final concentration is 85±5%, and after standing at 4±1°C for 24±2 hours, the precipitate is collected to obtain the crude polysaccharide from bean and taro leaves; 2), the purification of the crude polysaccharide from bean and taro leaves includes decolorizing the crude polysaccharides from bean and taro leaves with activated carbon and Sevage deproteinization.
Owner:ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products